Dosimetry in patients with B-cell lymphoma treated with [ (90) Y]ibritumomab tiuxetan or [ (131) I]tositumomab
Sjögreen-Gleisner, K.; Dewaraja, Y.K.; Chiesa, C.; Tennvall, J.; Lindén, O.; Strand, S.E.; Ljungberg, M.
Quarterly Journal of Nuclear Medicine and Molecular Imaging Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 55(2): 126-154
2011
ISSN/ISBN: 1824-4785 PMID: 21386787 Document Number: 648379
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the (90)Y-labeled ibritumomab and the (131)I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [(131)I]tositumomab and [(90)Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [(90)Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.